诺诚健华(688428.SH):多项肿瘤管线最新研究成果入选2025年ASCO年会

智通财经
08 Apr

智通财经APP讯,诺诚健华(688428.SH)发布公告,公司肿瘤管线ICP-248(Mesutoclax)、ICP-723(Zurletrectinib)和ICP-B05(CM369)最新研究成果入选2025年美国临床肿瘤学会(ASCO)大会,并将在大会上公布一系列在研管线最新数据。

2025年ASCO年会将于2025年5月30日到6月3日在芝加哥举办。ASCO年会是全球肿瘤领域权威的学术交流盛会,将展示当前国际前沿的临床肿瘤学科研成果和肿瘤治疗技术。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10